Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... YORK and LONDON , ...   FDNA Inc. ( http://www.fdna.com ) and ... that they have partnered to offer, for the first ... through FDNA,s solutions. FDNA, developer of the ... integrate LMD,s award-winning collection into Face2Gene [ TM ...
(Date:8/26/2014)... -- Based on its recent analysis of the breast imaging solutions ... North American Frost & Sullivan Award for Technology Innovation Leadership. ... solutions for the early detection of breast cancer. Over the ... solutions and has expanded its global reach to cover ... , Asia and Australia ...
(Date:8/26/2014)... , Aug. 26, 2014 Novira Therapeutics, ... for curative treatment of chronic hepatitis B virus (HBV) ... M.D., F.A.C.P., was appointed the Chair of its Scientific ... function as a Senior Advisor to the Company.  ... our SAB as Chair," said Christian Schade , ...
Breaking Medicine Technology:FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 2FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 3Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 2Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 3Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 4Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 5Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 3Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 4
... 2011 Advanced Cell Diagnostics (ACD), a technological ... provider for biomedical image and data analysis, announce ... applications that will enable researchers to accurately quantify ... clinical specimen. The partnership will build on ACD,s ...
... 31, 2011 Vanda Pharmaceuticals Inc. (Nasdaq: ... Phase IIb/III clinical trial of tasimelteon in patients with ... begin during the second half of 2011.  Tasimelteon is ... the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind ...
Cached Medicine Technology:Advanced Cell Diagnostics and Definiens Partner to Develop Tool for Quantitative Biomarker Analysis 2Advanced Cell Diagnostics and Definiens Partner to Develop Tool for Quantitative Biomarker Analysis 3Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression 2Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression 3Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression 4
(Date:8/27/2014)... (PRWEB) August 27, 2014 In My Solitude, ... Candle Collection” to provide a growing number of women from ... tool for goal setting and relaxing at the same time. ... candles, uses scent memory and visualization to help women stay ... life each time they light a candle and enjoy the ...
(Date:8/27/2014)... Atlanta, Georgia (PRWEB) August 27, 2014 ... subsidiary of PartnerTech AB, a major systems integration ... Impact Cryotherapy offering the first U.S. ... PartnerTech Inc. offered the ideal combination of manufacturing ... one-of-a-kind cryotherapy system. Impact Cryotherapy, headquartered in Atlanta, ...
(Date:8/26/2014)... NY (PRWEB) August 27, 2014 Hearing ... it can be hard for plan holders to determine what ... is now participating in several additional health plans and has ... and financial assistance page . , The following is ... Hearing is a participating provider: , NYSHIP/ NYS Empire Plan ...
(Date:8/26/2014)... Leelanau Peninsula Wine Trail ’s ... visit the region’s wineries. Rolling hills of grapevines cover ... fun in a weekend event that takes place September ... is an optional race through the vineyards at 9:00 ... A unique course between rows of grapevines offers an ...
(Date:8/26/2014)... Leelanau Peninsula, Michigan (PRWEB) August 26, 2014 ... awarded its first-ever recipients of the Bruce Simpson ... August 19. Four recipients will each receive $1,000 ... Kurtis Berry, Dawn Stemo, Alexis Bogdanova-Hanna and Ashley ... interested in pursuing careers as winemakers and vineyardists ...
Breaking Medicine News(10 mins):Health News:In My Solitude Unveils Eco Candle Line That May Improve Performance 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 3Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers One-of-a-Kind Walk or Run Through the Vineyards for Walkers, Runners and Wine Tasting Spectators Alike 2Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers One-of-a-Kind Walk or Run Through the Vineyards for Walkers, Runners and Wine Tasting Spectators Alike 3Health News:The Leelanau Peninsula Vintners Association (LPVA) Awards Its First-ever Bruce Simpson Winemakers Scholarships 2
... series feature eight model methods for effective prospect ... has released its first in a series of ... are using prospect research efficiently and with success ... fundraising, includes survey responses from 60 hospitals and ...
... 1 on annual listOAKLAND, Calif., March 5 ... has been recognized by DiversityMBA ... organization was ranked No. 1 in the publication,s fourth ... for Diverse Managers to Work," which will hit newsstands ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... for low intake of Omega-3 EPA/DHA amongst , childrenHALIFAX, ... the Journal of Nutrition found that most Canadian children ... 78% of the children trialed were not receiving adequate ... , Researchers from the University of Guelph ...
... ANGELES, March 5 With the nation focused on ... recently announced Assembly Bill 562 ( AB ... businesses and consumers that have fallen victim to price ... health care premium costs. It requires insurance companies to ...
... 5 Ascension Insurance, Inc. has announced ... Lauderdale, effective January 16th 2009. The agency specializes in ... (EMI), a member of the Ascension group of companies ... the Ascension group is managed by Ascension Insurance, Inc. ...
Cached Medicine News:Health News:WealthEngine Releases Best Practices Report for Healthcare Fundraising 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 2Health News:Kaiser Permanente Recognized as Best Place for Diverse Managers 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 2Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 3Health News:North American Children are Omega-3 Deficient and may be at risk for Suboptimal Health 4Health News:New Health Care Legislation Stops 'Opportunistic' Insurance Pricing 2Health News:Ascension Insurance, Inc. Acquires Fort Lauderdale-based Dennis Bartlett Agency 2
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
The base of the staple is round and threaded to enable screwing onto the stapler. The base also has spikes. The legs of the staple are contoured to prevent the staple from backing out....
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Medicine Products: